Novel Pharmacotherapies for Diabetic Macular Edema (DME)

Description

This template was adapted from the original submission. Edits were made to enhance scientific accuracy, optimal usability and/or to meet industry-leading design standards for science communication. Diabetic macular edema (DME) is the leading cause of vision loss in diabetic patients and is characterized by increased intraocular pressure and abnormal vessel growth in retinal area. Hyperglycemia in diabetes leads to up-regulation of inflammatory factors, and induces the breakdown of the blood-retinal barrier and fluid accumulation, ultimately causing macular swelling. This figure provides an overview of novel therapeutic strategies targeting different signaling pathways involved in the pathogenesis of DME.

Acknowledgements

References

Klaassen, Ingeborg et. al. (2013) Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Progress in retinal and eye research. https://pubmed.ncbi.nlm.nih.gov/23416119/ Urias, E. A et. al. (2017) Novel therapeutic targets in diabetic macular edema: Beyond VEGF. Vision Research. https://www.sciencedirect.com/science/article/pii/S0042698917301736?via%3Dihub Titchenell, P. M. et. al. (2013) Using the past to inform the future: anti-VEGF therapy as a road map to develop novel therapies for diabetic retinopathy. Diabetes. https://pubmed.ncbi.nlm.nih.gov/23704522/

Get started with this template for free

Don’t start from scratch.

Create professional scientific illustrations quickly and easily, even without any design expertise

Get started with a huge library of editable icons and templates such as common biological pathways, anatomy, or genetics.
Create figures that effectively communicate your research in half the time using our editable icons.
Use our PDB tool to quickly generate and customize protein structures

Get started now